



MCE has not independently confirmed the accuracy of these methods. They are for reference only.

|                 |   |
|-----------------|---|
| Animal Model:   | Twelve-week-old MWF rat <sup>[1]</sup>  |
| Dosage:         | 10 mg/kg  |
| Administration: | P.o.; daily for 4 weeks   |
| Result:         | Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model. |
| Animal Model:   | Twelve-week-old MWF rat <sup>[1]</sup>  |
| Dosage:         | 10 mg/kg  |
| Administration: | P.o.; daily for 4 weeks   |
| Result:         | Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model. |

## CUSTOMER VALIDATION

- Nature. 2023 Feb;614(7947):326-333.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Bärffacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403.

[2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA